Results 41 to 50 of about 28,652 (194)

The discovery of rivaroxaban: translating preclinical assessments into clinical practice

Frontiers in Pharmacology, 2013
Direct oral anticoagulants that target a single coagulation factor (such as factor Xa or thrombin) have been developed in recent years in an attempt to address some of the limitations of traditional anticoagulants.
Dagmar eKubitza, Elisabeth ePerzborn, Scott D Berkowitz   +2 more
doaj   +1 more source

Plasma Rivaroxaban Level in Patients With Early Stages of Chronic Kidney Disease—Relationships With Renal Function and Clinical Events

Frontiers in Pharmacology, 2022
Introduction Drug accumulation of rivaroxaban is a concern in patients with chronic kidney disease (CKD). Data regarding the plasma rivaroxaban levels in early CKD patients and its relationship with clinical events is lacking. Methods Early CKD patients (
Chun-Fung Sin, Ka-Ping Wong, Hoi-Man Wong, Chung-Wah Siu, Desmond Y. H. Yap   +4 more
doaj   +1 more source

Discontinuation of Rivaroxaban

Journal of the American College of Cardiology, 2013
Late in 2011, rivaroxaban became the first factor Xa inhibitor to receive regulatory approval for the prevention of stroke in patients with atrial fibrillation (AF), based largely on the results of the phase III ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared ...
openaire   +3 more sources

Efficacy and Safety of Rivaroxaban versus Warfarin for the Treatment of Acute Pulmonary Embolism: A Real-World Study

Analytical Cellular Pathology, 2020
Background. Pulmonary embolism (PE) is a life-threatening disease. Target-specific anticoagulant rivaroxaban is a direct factor Xa inhibitor that can be safely used without laboratory monitoring. Objective.
Yan Huang, Linli Duan, Wenjun He, Cheng Hong, Yehui Guo, Xinni Wang, Nuofu Zhang, Yanghang Chen, Tao Wang, Jian Wang, Chunli Liu   +10 more
doaj   +1 more source

Rivaroxaban prescribing in a Saudi tertiary care teaching hospital

Saudi Pharmaceutical Journal, 2018
Purpose: This drug utilization review (DUR) aimed to describe the use of rivaroxaban in a tertiary care teaching hospital and to audit the hospital physicians’ prescribing practice.
Ahmed Yacoob Mayet, Ahmed Ibrahim Alsaqer, Abdullah Musa Alhammad, Hussain Abdulrahman Al-Omar   +3 more
doaj  

Population Pharmacokinetics and Dose Optimization Based on Renal Function of Rivaroxaban in Thai Patients with Non-Valvular Atrial Fibrillation

Pharmaceutics, 2022
Low-dose rivaroxaban has been used in Asian patients with direct oral anticoagulants (DOACs) eligible for atrial fibrillation (AF). However, there are few pharmacokinetic (PK) data in Thai patients to support precise dosing. This study aimed to develop a
Noppaket Singkham, Arintaya Phrommintikul, Phongsathon Pacharasupa, Lalita Norasetthada, Siriluck Gunaparn, Narawudt Prasertwitayakij, Wanwarang Wongcharoen, Baralee Punyawudho   +7 more
doaj   +1 more source

Rivaroxaban in Patients with Heart Failure

New England Journal of Medicine, 2019
restriction
Jaewon Oh, Seok Min Kang
openaire   +4 more sources

Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study

Pharmaceuticals, 2012
Dual antiplatelet therapy with acetylsalicylic acid and a thienopyridine, such as clopidogrel, is effective for the secondary prevention of cardiovascular events in patients with acute coronary syndrome, but there is still a substantial residual risk of ...
Michael Becka, Wolfgang Mück, Stephan Schwers, Dagmar Kubitza   +3 more
doaj   +1 more source

Role of rivaroxaban after TAVI [PDF]

Nature Reviews Cardiology, 2019
Results of the GALILEO trial presented at the AHA Scientific Sessions 2019 indicate that a strategy with rivaroxaban 10 mg daily is associated with a higher risk of death or thromboembolic events and a higher risk of bleeding than an antiplatelet-based strategy.
openaire   +2 more sources

Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature [PDF]

Thrombosis Research, 2012
Rivaroxaban does not require monitoring nor frequent dose adjustment. However, searching for the optimal dose in the individual patient may be useful in some situations.To determine which coagulation assay could be used to assess the impact of rivaroxaban on haemostasis and provide guidelines for the interpretation of routine lab tests.Rivaroxaban was ...
Douxfils, J., Mullier, F., Dogné, J.-M., Loosen, C., Chatelain, B., Chatelain, C.   +5 more
openaire   +2 more sources